Allogene Therapeutics ALLO Stock
Allogene Therapeutics Price Chart
Allogene Therapeutics ALLO Financial and Trading Overview
| Allogene Therapeutics stock price | 2.06 USD |
| Previous Close | 2 USD |
| Open | 2.03 USD |
| Bid | 2.08 USD x 2800 |
| Ask | 4.28 USD x 100 |
| Day's Range | 2.01 - 2.17 USD |
| 52 Week Range | 0.98 - 4.46 USD |
| Volume | 6.57M USD |
| Avg. Volume | 10.34M USD |
| Market Cap | 724.82M USD |
| Beta (5Y Monthly) | 0.459 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.77 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.49 USD |
ALLO Valuation Measures
| Enterprise Value | 538.99M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.0693674 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.8437223 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -3.068 |
Trading Information
Allogene Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.459 |
| 52-Week Change | 63.93% |
| S&P500 52-Week Change | 24.48% |
| 52 Week High | 4.46 USD |
| 52 Week Low | 0.98 USD |
| 50-Day Moving Average | 2.17 USD |
| 200-Day Moving Average | 1.76 USD |
ALLO Share Statistics
| Avg. Volume (3 month) | 10.34M USD |
| Avg. Daily Volume (10-Days) | 8.84M USD |
| Shares Outstanding | 345.15M |
| Float | 270.67M |
| Short Ratio | 6.79 |
| % Held by Insiders | 11.02% |
| % Held by Institutions | 53.33% |
| Shares Short | 44.48M |
| Short % of Float | 14.25% |
| Short % of Shares Outstanding | 12.88% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -25.97% |
| Return on Equity (ttm) | -52.31% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | -131955000 USD |
| EBITDA | -175704992 USD |
| Net Income Avi to Common (ttm) | -173760000 USD |
| Diluted EPS (ttm) | -0.77 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 266.89M USD |
| Total Cash Per Share (mrq) | 0.77 USD |
| Total Debt (mrq) | 81.05M USD |
| Total Debt/Equity (mrq) | 29.06 USD |
| Current Ratio (mrq) | 9.647 |
| Book Value Per Share (mrq) | 1.139 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -109230000 USD |
| Levered Free Cash Flow (ttm) | -69944872 USD |
Profile of Allogene Therapeutics
| Country | United States |
| State | CA |
| City | South San Francisco |
| Address | 210 East Grand Avenue |
| ZIP | 94080 |
| Phone | 650 457 2700 |
| Website | https://allogene.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 150 |
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Q&A For Allogene Therapeutics Stock
What is a current ALLO stock price?
Allogene Therapeutics ALLO stock price today per share is 2.06 USD.
How to purchase Allogene Therapeutics stock?
You can buy ALLO shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Allogene Therapeutics?
The stock symbol or ticker of Allogene Therapeutics is ALLO.
Which industry does the Allogene Therapeutics company belong to?
The Allogene Therapeutics industry is Biotechnology.
How many shares does Allogene Therapeutics have in circulation?
The max supply of Allogene Therapeutics shares is 345.15M.
What is Allogene Therapeutics Price to Earnings Ratio (PE Ratio)?
Allogene Therapeutics PE Ratio is now.
What was Allogene Therapeutics earnings per share over the trailing 12 months (TTM)?
Allogene Therapeutics EPS is -0.77 USD over the trailing 12 months.
Which sector does the Allogene Therapeutics company belong to?
The Allogene Therapeutics sector is Healthcare.
Allogene Therapeutics ALLO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25587.04 USD — |
-2.21
|
13.51B USD — | 25513.26 USD — | 25882.57 USD — | — - | 13.51B USD — |
|
US Tech US 700 Small Cap Index
NQUS700SC
US
|
3090.39 USD — |
-0.26
|
— — | 3063.94 USD — | 3108.39 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12546.99 USD — |
-2.24
|
— — | 12513.27 USD — | 12692.24 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6185.56 USD — |
+0.85
|
— — | 6121.03 USD — | 6233.73 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1184.66 USD — |
+0.75
|
— — | 1174.72 USD — | 1192.68 USD — | — - | — — |
- {{ link.label }} {{link}}